Li J, Jia Z, Dong L, Cao H, Huang Y, Xu H
Biomark Res. 2024; 12(1):111.
PMID: 39334297
PMC: 11437670.
DOI: 10.1186/s40364-024-00653-2.
Coulson-Gilmer C, Littler S, Barnes B, Brady R, Anagho H, Pillay N
NAR Cancer. 2024; 6(3):zcae030.
PMID: 39015544
PMC: 11249981.
DOI: 10.1093/narcan/zcae030.
Zentout S, Imburchia V, Chapuis C, Duma L, Schutzenhofer K, Prokhorova E
Proc Natl Acad Sci U S A. 2024; 121(25):e2322689121.
PMID: 38865276
PMC: 11194589.
DOI: 10.1073/pnas.2322689121.
Wang Y, Liu X, Zuo X, Wang C, Zhang Z, Zhang H
Cell Genom. 2024; 4(5):100550.
PMID: 38697125
PMC: 11099347.
DOI: 10.1016/j.xgen.2024.100550.
Golan T, Raitses-Gurevich M, Beller T, Carroll J, Brody J
Cancer Treat Res. 2023; 186:125-142.
PMID: 37978134
DOI: 10.1007/978-3-031-30065-3_8.
Exploiting Cancer Synthetic Lethality in Cancer-Lessons Learnt from PARP Inhibitors.
Pettitt S, Ryan C, Lord C
Cancer Treat Res. 2023; 186:13-23.
PMID: 37978128
DOI: 10.1007/978-3-031-30065-3_2.
The function and regulation of ADP-ribosylation in the DNA damage response.
Duma L, Ahel I
Biochem Soc Trans. 2023; 51(3):995-1008.
PMID: 37171085
PMC: 10317172.
DOI: 10.1042/BST20220749.
Nanoengineered Gallium Ion Incorporated Formulation for Safe and Efficient Reversal of PARP Inhibition and Platinum Resistance in Ovarian Cancer.
Li Y, Cen Y, Tu M, Xiang Z, Tang S, Lu W
Research (Wash D C). 2023; 6:0070.
PMID: 36930754
PMC: 10013963.
DOI: 10.34133/research.0070.
Effect of the PARP inhibitor veliparib on germ cell tumor cell lines.
Schmidtova S, Udvorkova N, Cierna Z, Horak S, Kalavska K, Chovanec M
Oncol Lett. 2022; 24(5):392.
PMID: 36276487
PMC: 9533362.
DOI: 10.3892/ol.2022.13512.
PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues.
Murthy P, Muggia F
Cancer Drug Resist. 2022; 2(3):665-679.
PMID: 35582575
PMC: 8992523.
DOI: 10.20517/cdr.2019.002.
The expanding universe of PARP1-mediated molecular and therapeutic mechanisms.
Huang D, Kraus W
Mol Cell. 2022; 82(12):2315-2334.
PMID: 35271815
PMC: 9232969.
DOI: 10.1016/j.molcel.2022.02.021.
BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations.
Shah S, Rachmat R, Enyioma S, Ghose A, Revythis A, Boussios S
Int J Mol Sci. 2021; 22(23).
PMID: 34884434
PMC: 8657599.
DOI: 10.3390/ijms222312628.
Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models.
Coulson-Gilmer C, Morgan R, Nelson L, Barnes B, Tighe A, Wardenaar R
J Exp Clin Cancer Res. 2021; 40(1):323.
PMID: 34656146
PMC: 8520217.
DOI: 10.1186/s13046-021-02124-0.
Research progress of omics technology in the field of tumor resistance: From singleomics to multiomics combination application.
Sun Z, Liu Y, Ouyang Q, Liu Z, Liu Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021; 46(6):620-627.
PMID: 34275931
PMC: 10930197.
DOI: 10.11817/j.issn.1672-7347.2021.200561.
Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
Kim D, Camacho C, Kraus W
Exp Mol Med. 2021; 53(1):42-51.
PMID: 33487630
PMC: 8080675.
DOI: 10.1038/s12276-021-00557-3.
ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells.
Verma P, Zhou Y, Cao Z, Deraska P, Deb M, Arai E
Nat Cell Biol. 2021; 23(2):160-171.
PMID: 33462394
PMC: 7880902.
DOI: 10.1038/s41556-020-00624-3.
ADP-ribosylhydrolases: from DNA damage repair to COVID-19.
Yu L, Liu X, Yu X
J Zhejiang Univ Sci B. 2021; 22(1):21-30.
PMID: 33448184
PMC: 7818011.
DOI: 10.1631/jzus.B2000319.
The chromatin remodeler ALC1 underlies resistance to PARP inhibitor treatment.
Juhasz S, Smith R, Schauer T, Spekhardt D, Mamar H, Zentout S
Sci Adv. 2020; 6(51).
PMID: 33355125
PMC: 11206534.
DOI: 10.1126/sciadv.abb8626.
Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?.
Klotz D, Wimberger P
Arch Gynecol Obstet. 2020; 302(5):1087-1102.
PMID: 32833070
PMC: 7524817.
DOI: 10.1007/s00404-020-05677-1.
Interferon-stimulated gene 15 accelerates replication fork progression inducing chromosomal breakage.
Raso M, Djoric N, Walser F, Hess S, Schmid F, Burger S
J Cell Biol. 2020; 219(8).
PMID: 32597933
PMC: 7401800.
DOI: 10.1083/jcb.202002175.
